Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo Inc. develops and markets wearable medical robotics for people with neurological disorders and upper-limb paralysis. Its MyoPro product line is a powered upper-limb orthosis that uses non-invasive EMG sensors to support weakened or paralyzed arms in patients with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury and other neuromuscular disease or injury.
Company news commonly covers MyoPro orders, insurance authorizations, patient-pipeline trends, revenue from recurring patient sources, market-access relationships with orthotics and prosthetics providers, and product-development updates such as the Myomo Mobile App. Updates also include clinical research evaluating MyoPro, operating results, direct-billing activity, international sales channels and board governance changes.
Myomo (NYSE American: MYO) reported second quarter 2026 revenue of $11.7 million, up 21% year over year, with 53% of revenue from recurring referral sources via MyoConnect and other channels. The company recognized revenue on 211 MyoPro units and achieved an average selling price of about $55,500, up 2%.
Gross margin rose to 72.1% from 62.7%, lifting gross profit to $8.4 million. Operating expenses were $10.7 million, up less than 1%, driving an operating loss improvement to $2.3 million from $4.6 million and an Adjusted EBITDA loss of $0.8 million versus $4.0 million. Net loss was $4.0 million ($0.09 per share). Cash, cash equivalents and short-term investments totaled $13.5 million, with operating cash use of $1.9 million versus $8.9 million a year earlier.
Myomo raised its 2026 revenue guidance to $45–$47 million, implying approximately 10–15% growth, and guided Q3 2026 revenue to $11.5–$12.0 million, up 14–19% year over year.
Myomo (NYSE American: MYO) announced it will report second quarter 2026 financial results, for the period ended June 30, 2026, on Wednesday, August 5, 2026. Management will host a conference call at 4:30 p.m. Eastern time to review results, discuss the business and take questions.
Investors can pre-register to receive a dial-in number and PIN, or join by calling 844-707-6932 (U.S.) or 412-317-9250 (International). A live webcast and replay will be available at https://ir.myomo.com/, with dial-in replay access through August 19, 2026 using code 1135727.
Myomo (NYSE American: MYO) announced participation in two virtual investor conferences on May 20-21, 2026. President and CEO Paul Gudonis and CFO David Henry will join a fireside chat at the Alliance Global Partners Annual Healthcare Company Showcase at 11:20 a.m. ET on May 20.
CFO David Henry will also present at Sidoti’s Virtual Micro Cap Conference, with a live webcast scheduled for 1:45 p.m. ET on May 21 and one-on-one investor meetings throughout the event.
Myomo (NYSE American: MYO) appointed Joseph M. “Joe” Manko Jr. to its Board of Directors, effective May 9, 2026, serving until the 2027 annual meeting. With his addition, the board now has seven directors.
Manko, Senior Principal and founder of Horton Capital Management, a significant shareholder, brings over 25 years of experience in investment banking, private equity, asset management, corporate strategy, and corporate governance, plus prior roles at Deutsche Bank, Merrill Lynch, and Skadden Arps.
Myomo (NYSE: MYO) reported Q1 2026 revenue of $10.1M, up 3% year-over-year, with 49% of revenue from recurring patient sources. Gross margin expanded to 68.2%, operating expenses fell 1%, and Adjusted EBITDA improved to $(2.3)M. Cash and short-term investments were $15.7M. Backlog was 226 patients; 239 orders received, up 12% YoY. Company reaffirmed full-year revenue guidance of $43M–$46M and Q2 revenue outlook of $10.3M–$10.8M.
Myomo (NYSE American: MYO) announced expanded availability of the MyoPro powered arm brace through Ottobock Care clinics across the U.S. Ottobock Care will offer fittings and clinical support; Myomo says clinicians have been trained and several patients have already been fitted.
The company noted that Medicare and a growing number of insurers cover MyoPro on a case-by-case basis.
Myomo (NYSE American: MYO) will report first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, May 7, 2026. Management will host a conference call at 4:30 p.m. ET to review results, provide a business update and answer questions. A webcast, live dial-in numbers, pre-registration link, and replays will be available via the investor site.
Myomo (NYSE American: MYO) launched the Myomo Mobile App on April 20, 2026 to improve clinician workflow and patient engagement for MyoPro users. The app enables remote and in-person EMG configuration, real-time muscle-activity visualizations, usage tracking, training resources, and supports expanded data capture for future analytics.
Myomo (NYSE American: MYO) appointed William "Will" Febbo to its board effective April 14, 2026, to serve until the 2028 annual meeting of stockholders, bringing the board to six directors.
Febbo has 30+ years of healthcare, financial services and technology experience, recently joined Performance Health Systems in February 2026, and previously grew OptimizeRx revenue from $5M to $92M with a five-year CAGR of 41%.
Myomo (NYSE: MYO) reported Q4 2025 revenue of $11.4M and full-year 2025 revenue of $40.9M, a 26% increase versus 2024. Q4 included 241 orders and 42% revenue from recurring patient sources. GAAP net loss was $15.6M for 2025; cash and short-term investments were $18.4M. Management guided 2026 revenue to $43M–$46M and expects reduced cash burn and improved operating leverage while pursuing recurring channels and marketing initiatives.